Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Sta...
Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring in...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results o...
Continued commercial and strategic execution delivers sequential core revenue growth of 4% – 9% to $26 million – $27 million in Q4 2022 for full year total of approximately $94 million – $95 million Business restructuring and SBS prog...
Fluidigm (NASDAQ:FLDM) on Monday closed the strategic capital infusion from investors Casdin Capital and Viking Global Investors. Fluidigm has been renamed Standard BioTools and its stock is expected to begin trading on Nasdaq under the symbol "LAB" as of market open on Apr. 6. Jeremy Da...
New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SO...
Gainers: SPI Energy (SPI) +36%. Workday (WDAY) +11%. TMC the metals company (TMC) +10%. ThredUp (TDUP) +7%. WAVE Life Sciences (WVE) +4%. Losers: CRISPR Therapeutics (CRSP) -7%. ImmunoGen (IMGN) -5%. Ionis Pharmaceuticals (IONS) -5%. Radius Health (RDUS) -5%. Fluidigm (FLDM) -4%. ...
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capi...
Life sciences company, Fluidigm Corporation (FLDM +9.1%), announced on Tuesday that its largest shareholder, Caligan Partners, agreed to support all proposals related to the proposed strategic capital infusion from Casdin Capital, LLC and Viking Global Investors LP. Per the terms, Caligan has...
Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transact...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...